Ingegnoli, Francesca ORCID: 0000-0002-6727-1273, Schioppo, Tommaso, Allanore, Yannick, Caporali, Roberto, Colaci, Michele, Distler, Oliver ORCID: 0000-0002-0546-8310, Furst, Daniel E., Hunzelmann, Nicolas, Lannone, Florenzo, Khanna, Dinesh and Matucci-Cerinic, Marco (2019). Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Semin. Arthritis Rheum., 48 (4). S. 686 - 694. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1532-866X

Full text not available from this repository.

Abstract

Background: Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by vascular impairment, immune dysfunction and collagen deposition. Raynaud's phenomenon (RP) and digital ulcers (DU) are prominent features of SSc. Intravenous (IV) iloprost (ILO), according to the recently updated EULAR recommendations, is indicated for RP after failure of oral therapy. Moreover, IV ILO could be useful in DU healing. IV ILO is currently available mainly on the European market approved for RP secondary to SSc with 3-5 days infusion cycle. Unfortunately, data published varies regarding regimen (dosage, duration and frequency). Up to now, ILO has been studied in small cohorts of patients and in few randomized controlled trials. Methods: A systematic review of studies on IV ILO in patients with SSc complicated by DU and RP was performed. Insufficient data were available to perform a meta-analysis according to the GRADE system. We performed a three-stage internet-based Delphi consensus exercise. Results: Three major indications were identified for IV ILO usage in SSc: RP non-responsive to oral therapy, DU healing, and DU prevention. IV ILO should be administered between 0.5 and 2.0 ng/kg/min according to patient tolerability with a frequency depending on the indication. Conclusions: Although these suggestions are supported by this expert group to be used in clinical setting, it will be necessary to formally validate the present suggestions in future clinical trials. (C) 2018 Elsevier Inc. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Ingegnoli, FrancescaUNSPECIFIEDorcid.org/0000-0002-6727-1273UNSPECIFIED
Schioppo, TommasoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Allanore, YannickUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Caporali, RobertoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Colaci, MicheleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Distler, OliverUNSPECIFIEDorcid.org/0000-0002-0546-8310UNSPECIFIED
Furst, Daniel E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hunzelmann, NicolasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lannone, FlorenzoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Khanna, DineshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Matucci-Cerinic, MarcoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-157326
DOI: 10.1016/j.semarthrit.2018.03.019
Journal or Publication Title: Semin. Arthritis Rheum.
Volume: 48
Number: 4
Page Range: S. 686 - 694
Date: 2019
Publisher: W B SAUNDERS CO-ELSEVIER INC
Place of Publication: PHILADELPHIA
ISSN: 1532-866X
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SCLERODERMA; THERAPY; MANAGEMENT; INFUSIONS; QUALITYMultiple languages
RheumatologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/15732

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item